Amgen Terminates Advaxis Immunotherapy Collaboration and Other Deal Terminations
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 12 (Table of Contents)
Published: 29 Dec-2018
DOI: 10.3833/pdr.v2018.i12.2390 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a surprise move, Amgen has decided to conclude its immunotherapy collaboration with Advaxis to develop and commercialise the latter’s Phase I asset, ADXS-NEO, a personalised cancer immunotherapy treatment...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS